ArticlePloS one2025
Biosynthesis and characterization of silver nanoparticles from Asplenium dalhousiae and their potential biological properties.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Silver Nanoparticles as Anticancer Agents: Mechanisms Insight, Current Studies, and Limitations.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the green synthesis of silver nanoparticles (AgNPs) using the medicinal plant Asplenium dalhousiae focusing on its bioactive chemical constituents as natural reducing agents. Aqueous, chloroform, and n-hexane extracts of the plant leaves were utilized in the nanoparticle synthesis process. The synthesized AgNPs were confirmed through UV-visible spectroscopy, showing absorption peaks at approximately 420 nm, 443 nm, and 439 nm. Fourier-transform infrared (FTIR) spectroscopy was used to recognize the functional groups in the plant extracts responsible for facilitating the reduction process. The morphological and structural characteristics of the synthesized nanoparticles were analyzed using Scanning Electron Microscopy (SEM) and X-ray Diffraction (XRD). These analyses revealed that the nanoparticles synthesized using the Aqueous, chloroform, and n-hexane extracts were predominantly spherical silver nanoparticles (AgNPs) with a crystalline structure and an average diameter of 46.98 ± 12.45 nm, as determined by SEM. The antibacterial efficacy of the synthesized AgNPs was evaluated against Escherichia coli, Bacillus subtilis, and Pseudomonas aeruginosa at a concentration of 30 μg/ml. Among the tested nanoparticles, the AgNPs synthesized from the n-hexane extract exhibited the highest antibacterial activity, with zones of inhibition measuring 20.0 ± 1.8 mm for E. coli, 19.0 ± 1.2 mm for B. subtilis, and 19.5 ± 1.4 mm for P. aeruginosa. Additionally, the silver nanoparticles (AgNPs) from Asplenium dalhousiae demonstrated significant α-amylase inhibition, with 85.04% inhibition at 500 µg/ml, compared to Acarbose (90.84%) and the leaf extract (78.65%). The antioxidant activity of the synthesized AgNPs was assessed using the DPPH method, which confirmed their significant antioxidant properties alongside their antibacterial activity. The aqueous and n-hexane silver nanoparticles (AgNPs) showed strong cytotoxic activity with low IC50 values, particularly in A2780 cells (15.76 µg/ml and 9.11 µg/ml, respectively), while the plant methanolic extract and CHCl3 AgNPs exhibited much higher IC50 values, indicating moderate to low activity. This study highlights the potential of AgNPs in handling anticancer, α-amylase, and antibacterial infections. By assimilating natural products with nanotechnology, it deals an inventive approach to developing targeted, eco-friendly therapies, paving the way for cutting-edge biomedical applications and improved treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.